Hidradenitis suppurativa is a chronic inflammatory dermatosis characterized by painful, recurrent nodules, abscesses, and draining tunnels, known as sinus tracts, most commonly in the axillae, groin, and perineal regions. It arises from inflammation centered on the hair follicles in areas rich in apocrine glands, and it follows a relapsing-remitting course that can span decades. The disease is far from rare, affecting an estimated one percent or more of the population, yet it remains underdiagnosed and frequently mistaken for simple boils or infections. Beyond its physical toll, the condition is notorious for its impact on quality of life: lesions in sensitive body regions, malodorous drainage, scarring, and unpredictable flares contribute to social isolation, sexual dysfunction, and profound psychological distress. For years, clinicians have observed that patients with hidradenitis suppurativa suffer from depression, anxiety, and suicidality at rates that dwarf those seen in the general population and in many other chronic dermatologic diseases.

What distinguishes the new research letter by Rehman Basharat of the Renaissance School of Medicine at Stony Brook University and Javed Iqbal of Stony Brook’s Department of Neurobiology and Behavior is its deliberate reversal of the conventional causal arrow. Most prior investigations, including a widely cited 2020 systematic review and meta-analysis published in the Journal of the American Academy of Dermatology, examined depression, anxiety, and suicidality as outcomes of living with hidradenitis suppurativa. That meta-analysis confirmed strikingly elevated odds of psychiatric comorbidity among patients, cementing the skin-to-mind pathway in the literature. The Stony Brook team instead asked whether depression might come first—whether a diagnosis of depression increases the subsequent likelihood of developing hidradenitis suppurativa. By structuring the analysis as a retrospective cohort using real-world data, the investigators could track individuals over time and examine the temporal sequence between the psychiatric and dermatologic conditions, an approach that cross-sectional surveys simply cannot support.

The biologic plausibility of such a reverse pathway rests on a rapidly growing understanding of the immunology of depression itself. Far from being a purely neurochemical disorder, major depression is increasingly recognized to carry a systemic inflammatory signature. Landmark work, including the influential 2016 review by Andrew Miller and Charles Raison in Nature Reviews Immunology, has documented elevated circulating pro-inflammatory cytokines, increased acute-phase reactants, and altered immune cell activity in subsets of depressed patients. Cytokines such as interleukin-1 beta, interleukin-6, and tumor necrosis factor alpha can cross into or signal within the central nervous system, but their effects are by no means confined to the brain. These same molecular messengers are central drivers of cutaneous inflammation. In hidradenitis suppurativa specifically, the pathophysiology is understood to involve follicular occlusion followed by an intense, dysregulated immune response dominated by innate inflammatory pathways and a characteristic overexpression of tumor necrosis factor alpha, interleukin-17, and interleukin-23 in lesional skin. A 2024 narrative review in Skin Appendage Disorders meticulously mapped this cytokine-mediated molecular architecture of the disease, highlighting how TNF-alpha in particular orchestrates the chronic inflammatory cascade that destroys follicular structures and produces the fistulating lesions that define advanced disease.

The convergence of these two inflammatory profiles is what gives the new hypothesis its scientific traction. Depression is associated with elevated TNF-alpha and other cytokines; hidradenitis suppurativa is driven by the same mediators. If a state of chronic, low-grade systemic inflammation induced or maintained by depression were to lower the threshold for follicular inflammation, impair wound healing, or dysregulate the innate immune responses of the skin, then depressed individuals could plausibly face a heightened risk of developing manifest hidradenitis suppurativa. Behavioral and physiological factors common to depression may compound this immunologic pathway: sleep disruption, physical inactivity, smoking, obesity, poor diet, and altered hypothalamic-pituitary-adrenal axis activity are all more prevalent in depression and all have documented links to inflammatory skin disease severity. Cortisol dysregulation, in particular, is known to impair epidermal barrier function and dermal immune surveillance, mechanisms that have been studied extensively in the psychodermatology literature.

The Stony Brook authors are explicit that their work builds on earlier speculation in the field. A 2024 commentary in the journal Cutis raised exactly this possibility, arguing that depression could function as a potential contributing factor in hidradenitis suppurativa and highlighting racial gaps in how the association manifests, given the disease’s disproportionate burden on Black patients and the documented disparities in diagnosis and treatment access. A 2023 literature review in the journal Life catalogued the range of psychiatric disorders associated with hidradenitis suppurativa and explored their potential pathogenesis, concluding that the relationship is almost certainly bidirectional and biologically embedded rather than a simple byproduct of living with visible, painful lesions. By bringing retrospective cohort methodology and real-world data to bear, the new research letter provides an empirical test of what had been largely a hypothesis grounded in mechanistic plausibility and clinical observation.

The real-world data approach deserves particular emphasis, because it addresses a persistent weakness of the hidradenitis suppurativa literature. Randomized trials in the field, including those that established biologics such as TNF-alpha and IL-17 inhibitors as mainstay therapies, enroll selected patients under controlled conditions, and their findings do not always translate cleanly to the heterogeneous populations seen in routine practice. Recent real-world studies, such as 2025 evaluations of biologic therapy effectiveness published in the Australasian Journal of Dermatology, have demonstrated both the value and the limitations of translating trial results into everyday clinical care, including nuances in lipid profiles and treatment safety captured only in broader cohorts. A retrospective cohort built on real-world data captures patients of all disease severities, comorbidity profiles, and demographic backgrounds, offering a view of the depression-hidradenitis axis that reflects the population as it actually presents to clinicians rather than as it appears in protocol-driven trials.

For clinicians, the implications of a depression-to-hidradenitis risk pathway would be considerable. Dermatologists managing patients with early or suspected hidradenitis suppurativa routinely screen for psychiatric comorbidity, and European S1 guidelines for the disease’s treatment explicitly recommend attention to quality of life and psychological burden as part of comprehensive care. But if depression is also a risk factor, the screening logic inverts: psychiatrists and primary care physicians treating depressed patients, particularly those with inflammatory comorbidities, obesity, or smoking, might reasonably maintain a heightened index of suspicion for early follicular inflammation in intertriginous areas, enabling diagnosis before the disease progresses to painful scarring and sinus tract formation. Early intervention matters enormously in this disease, since treatments ranging from wound care and antibiotics to biologics and surgery are far more effective before irreversible structural damage occurs. The findings also raise provocative questions about whether effective depression treatment could modify hidradenitis risk, an intervention trial that no one has yet conducted but that the current study’s results would seem to justify.

The authors are careful to frame their work within the constraints of the retrospective design. Observational cohort data can establish temporal sequence and statistical association, but cannot by itself prove causation; unmeasured confounders, including shared genetic susceptibilities, medication effects, and healthcare utilization patterns, may partly explain the observed relationship. The research letter format likewise signals a concise, focused analysis intended to stimulate further work rather than to settle the question definitively. Both authors contributed to writing the manuscript, with Basharat preparing the figure and table, and both reviewed and approved the final text. The authors declare no competing interests, and the data supporting the findings are provided within the manuscript itself. Correspondence for the study is directed to Javed Iqbal in Stony Brook’s Department of Neurobiology and Behavior.

Nevertheless, the study lands at a moment when the broader concept of the mind-skin axis is gaining scientific respectability. Psychodermatology, once a niche corner of both dermatology and psychiatry, now commands growing attention as immunologic research reveals the molecular common ground between mental states and skin inflammation. The inflammatory hypothesis of depression has prompted trials of anti-inflammatory agents as antidepressant adjuncts; conversely, dermatologists increasingly recognize that calming systemic inflammation can lift mood. Hidradenitis suppurativa, with its uniquely severe psychiatric comorbidity burden and its cytokine biology so clearly intertwined with the inflammatory signature of depression, may prove to be one of the clearest natural laboratories for studying this bidirectional relationship. If future prospective studies confirm that depression accelerates or precipitates the disease, the Standard of care could expand to include collaborative, multidisciplinary management in which mental health treatment is viewed not only as supportive care but as a genuine component of dermatologic prevention. For the millions of patients who endure this condition in silence, often for years before diagnosis, the recognition that their psychological suffering and their skin disease are two faces of a single inflammatory biology represents both scientific progress and long-overdue clinical empathy.

Hidradenitis suppurativa is a chronic, painful, and often disfiguring inflammatory disorder characterized by recurrent abscesses, nodules, and extensive scarring primarily affecting intertriginous areas such as the armpits, groin, and under the breasts. Despite decades of research, its complex pathophysiology has remained incompletely understood, with multifactorial contributions including genetics, immune dysregulation, microbiome perturbations, and environmental triggers. The present study marks a significant leap forward by identifying IgA autoantibodies as central mediators capable of igniting and sustaining the inflammatory cascades and fibrotic outcomes that hallmark HS lesions.

The research team utilized an integrative approach combining patient sample analyses, in vitro immunologic assays, and in vivo murine models to dissect the role of IgA autoantibodies in HS pathogenesis. They initially identified elevated levels of these autoantibodies in the serum and lesional skin of HS patients, correlating with disease severity and chronicity. This prompted detailed exploration into the mechanistic underpinnings of how IgA antibodies influence local immune environments and cellular behaviors within affected tissues.

A key discovery was that IgA autoantibodies bind to specific autoantigens expressed in the skin, triggering an intense inflammatory milieu. This interaction leads to the activation of innate immune cells such as neutrophils and macrophages, which amplify tissue damage through the release of proteases and reactive oxygen species. Importantly, this inflammatory state appears to prime adaptive immunity towards a Th17-dominant response, characterized by elevated secretion of interleukin-17 (IL-17) and related cytokines known to perpetuate chronic inflammation and tissue remodeling.

The Th17 polarization induced by IgA autoantibodies is of particular interest because IL-17-driven pathways have been increasingly recognized as critical in autoimmune and autoinflammatory diseases. The study demonstrates that the skewing towards Th17 responses underlies much of the immune dysregulation observed in HS, providing a crucial link between autoantibody activity and adaptive immunity disturbances. By locating this immunological axis at the center of HS pathophysiology, the research opens the door for targeted modulation of Th17 pathways as a therapeutic strategy.

Fibrosis, or excessive scar tissue formation, is another devastating manifestation of HS, leading to permanent architectural alterations and chronic disability. Carmona-Rivera’s group shows that IgA autoantibodies not only promote inflammation but also directly contribute to fibrotic responses by activating fibroblasts and myofibroblasts within the skin. These cells produce excess extracellular matrix components such as collagen, leading to the dense scar tissue that characterizes chronic HS lesions. This dual role of IgA autoantibodies in fueling both inflammation and fibrosis adds a new dimension to their pathological significance.

The study further elucidates the signaling pathways triggered by IgA-autoantigen complexes. Activation of Fc alpha receptors (FcαR) on immune cells initiates downstream cascades involving nuclear factor kappa B (NF-κB) and mitogen-activated protein kinases (MAPKs), culminating in the secretion of pro-inflammatory cytokines and chemokines. Concurrently, these signaling events stimulate fibroblast proliferation and matrix production, linking immune activation directly with fibrotic remodeling. These insights lay a molecular foundation for future drug development targeting FcαR-mediated signaling in HS.

Importantly, the researchers validated their findings using mouse models genetically engineered to express human Fcα receptors and featuring induced HS-like skin lesions. Administration of IgA autoantibodies in these models reproduced hallmark features of human HS, including inflammation, Th17 skewing, and fibrosis, confirming the pathological role of IgA autoimmunity in vivo. Moreover, therapeutic blockade of FcαR or neutralization of IL-17 ameliorated disease markers, highlighting viable pathways for clinical intervention.

This seminal work challenges existing paradigms by positioning IgA autoantibodies—not typically associated with autoimmune diseases like systemic lupus erythematosus or rheumatoid arthritis—as central actors in HS. The findings prompt reconsideration of HS as an autoimmune disease with distinct immunopathogenic signatures driven by IgA rather than IgG, potentially explaining its unique clinical course and refractory nature to conventional immunosuppression.

Clinically, these discoveries carry profound implications. Measurement of serum IgA autoantibody levels and detection of their corresponding skin autoantigens could provide valuable biomarkers for disease activity, prognosis, and therapeutic response. Furthermore, therapies designed to dampen IgA autoantibody production, block their interaction with Fcα receptors, or inhibit downstream Th17-driven cytokines represent innovative treatment modalities that could revolutionize HS management by addressing root causes rather than merely controlling symptoms.

Beyond hidradenitis suppurativa, the study raises intriguing questions about the broader role of IgA autoimmunity in other chronic inflammatory and fibrotic disorders. Similar mechanisms of IgA-driven inflammation and fibrosis might exist in conditions affecting mucosal and epithelial interfaces, such as inflammatory bowel disease or fibrosing dermopathies. Thus, the conceptual advance offered by Carmona-Rivera and colleagues may have wide-ranging translational impact across immunodermatology and beyond.

As the scientific community digests these findings, ongoing research is likely to focus on elucidating the triggers for IgA autoantibody production in HS patients, such as microbial dysbiosis or genetic predispositions, and on refining therapies that specifically target the FcαR-Th17-fibrosis axis unveiled here. Large-scale clinical trials testing FcαR antagonists or IL-17 inhibitors in HS cohorts informed by autoantibody profiles could usher in a new era of precision medicine for this neglected and stigmatizing disease.

In conclusion, the discovery that IgA autoantibodies orchestrate inflammation, Th17 polarization, and fibrotic responses in hidradenitis suppurativa provides a paradigm-shifting framework for understanding and treating this complex skin disorder. The meticulous mechanistic studies and translational relevance underscore the potential of targeting IgA-driven pathways to mitigate disease and improve quality of life for HS patients worldwide. This landmark research opens previously uncharted paths in immunodermatology and paves the way for transformative therapeutic innovations.

Subject of Research: The role of IgA autoantibodies in driving inflammation, Th17 immune polarization, and fibrosis in hidradenitis suppurativa.

Article Title: IgA autoantibodies promote inflammation, Th17 polarization and fibrotic responses in hidradenitis suppurativa.

Article References:
Carmona-Rivera, C., O’Neil, L.J., Patino-Martinez, E. et al. IgA autoantibodies promote inflammation, Th17 polarization and fibrotic responses in hidradenitis suppurativa. Nat Commun (2026). https://doi.org/10.1038/s41467-026-70883-5

Image Credits: AI Generated